MacroChem acquires rights to Pexiganan from Genaera
Broadens late-stage product development portfolio building on lead product candidate EcoNail in Phase 2 trial for onychomycosis
08-Oct-2007 -
MacroChem Corporation announced that it has exercised the option it acquired in July, 2007 to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for treatment of patients with mild diabetic foot infection (DFI), from Genaera ...
anti-infectives
chemistry
clinical trials
+2